drugset
drugset / Trial / NCT02104336

Phase 2 Study of EPI-743 in Children With Pearson Syndrome

NCT02104336 ↗

Phase 2 Terminated 2 enrolled Edison Pharmaceuticals Inc
NaSingle-groupOpen-labelTreatment

Summary

Treatment of Pediatric Subjects with Pearson syndrome

Timeline

Start
2014-08-31
Primary completion
2015-11-30
Completion
2016-02-29

Outcome

Outcome not reported

Stopped: “Results from other studies did not support continuation of this trial”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vatiquinone Small molecule 15 mg/kg —

Indications

Pearson syndrome